長春高新(000661.SZ)連續兩日跌停
格隆匯1月20日丨長春高新(000661.SZ)繼昨日閃崩跌停後,開盤再度一字跌停,現報204.84元,封單逾9萬手,暫成交7億元,最新市值829億元。

針對公司的生長激素產品被納入了廣東省的藥品集採,長春高新在互動平台表示,廣東省藥交中心網站今日公佈了相關集中帶量採購文件,公司目前正在積極研究政策規定並將合理制定方案,目前暫無具體影響的預期。
廣東省藥品交易中心昨日發佈《廣東聯盟雙氯芬酸等藥品集中帶量採購文件》的通知,在276個藥品採購清單中,包括長春金賽藥業有限責任公司的1種規格的重組人生長激素注射液(30IU/10mg/3ml)和3種規格的注射用重組人生長激素(注射用無菌粉末),規格分別為10IU、2.5IU和4.5IU。其中,重組人生長激素注射液(30IU/10mg/3ml)的最高有效申報價為295.0785元/支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.